IRONWOOD PHARMACEUTICALS, INC. (IRWD) Scorecard
- 2026-Q2: Total return Win; Revenue growth Win; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Win; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Win; Revenue growth Lose; EPS growth Lose.
41/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 6 wins, 6 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q22/3 |
WinIRWD / S&P 19.94% / 15.20% |
WinIRWD / S&P 26.19% / 15.00% |
LoseIRWD / S&P -1640.00% / 50.40% |
| 2026-Q12/3 |
WinIRWD / S&P 4.15% / -4.33% |
WinIRWD / S&P 13.80% / 11.30% |
LoseIRWD / S&P -400.00% / 27.70% |
| 2025-Q41/3 |
WinIRWD / S&P 157.25% / 2.65% |
LoseIRWD / S&P -15.72% / 9.00% |
LoseIRWD / S&P IRWD unavailable / 13.40% |
| 2025-Q31/3 |
WinIRWD / S&P 81.94% / 8.12% |
LoseIRWD / S&P -10.42% / 4.61% |
LoseIRWD / S&P -900.00% / 13.45% |
| 2025-Q20/3 |
LoseIRWD / S&P -51.02% / 10.94% |
LoseIRWD / S&P -22.98% / 4.83% |
LoseIRWD / S&P -200.00% / 10.63% |
| 2025-Q10/3 |
LoseIRWD / S&P -66.82% / -4.27% |
LoseIRWD / S&P -23.18% / 4.98% |
LoseIRWD / S&P -97.05% / 10.57% |
| 2024-Q41/3 |
WinIRWD / S&P 7.52% / 2.41% |
LoseIRWD / S&P -20.63% / 5.25% |
LoseIRWD / S&P -100.00% / 6.15% |
| 2024-Q30/3 |
LoseIRWD / S&P -36.81% / 5.89% |
LoseIRWD / S&P -12.48% / 5.89% |
LoseIRWD / S&P -99.68% / 6.11% |
| 2024-Q20/3 |
LoseIRWD / S&P -25.14% / 4.28% |
LoseIRWD / S&P -6.25% / 5.38% |
LoseIRWD / S&P -100.83% / 5.12% |
| 2024-Q10/3 |
LoseIRWD / S&P -23.86% / 10.56% |
LoseIRWD / S&P -0.86% / 5.71% |
LoseIRWD / S&P -771.29% / 5.59% |
| 2023-Q42/3 |
WinIRWD / S&P 18.80% / 11.69% |
WinIRWD / S&P 7.83% / 6.81% |
LoseIRWD / S&P -770.10% / 7.78% |
| 2023-Q30/3 |
LoseIRWD / S&P -9.49% / -3.27% |
LoseIRWD / S&P 2.82% / 7.52% |
LoseIRWD / S&P -762.77% / -5.03% |
| 2023-Q20/3 |
LoseIRWD / S&P 1.14% / 8.74% |
LoseIRWD / S&P 2.80% / 9.50% |
LoseIRWD / S&P -704.00% / -8.57% |
| 2023-Q10/3 |
LoseIRWD / S&P -15.09% / 7.50% |
LoseIRWD / S&P -1.26% / 10.77% |
LoseIRWD / S&P -68.24% / -15.69% |
| 2022-Q41/3 |
WinIRWD / S&P 19.59% / 7.56% |
LoseIRWD / S&P -0.76% / 11.88% |
LoseIRWD / S&P -69.88% / -17.99% |
| 2022-Q30/3 |
LoseIRWD / S&P -10.15% / -4.88% |
LoseIRWD / S&P 1.75% / 13.47% |
LoseIRWD / S&P -71.08% / -1.41% |
| 2022-Q21/3 |
WinIRWD / S&P -8.35% / -16.10% |
LoseIRWD / S&P 0.63% / 13.71% |
LoseIRWD / S&P -67.95% / 11.04% |
| 2022-Q12/3 |
WinIRWD / S&P 7.89% / -4.60% |
LoseIRWD / S&P 6.03% / 15.97% |
WinIRWD / S&P 257.30% / 42.23% |
| 2021-Q41/3 |
LoseIRWD / S&P -10.72% / 11.03% |
LoseIRWD / S&P 6.22% / 15.00% |
WinIRWD / S&P 387.88% / 96.40% |
| 2021-Q32/3 |
WinIRWD / S&P 1.48% / 0.58% |
LoseIRWD / S&P 3.55% / 10.77% |
WinIRWD / S&P 364.29% / 69.42% |
| 2021-Q22/3 |
WinIRWD / S&P 15.12% / 8.55% |
LoseIRWD / S&P -3.24% / 6.58% |
WinIRWD / S&P 403.23% / 51.81% |
| 2021-Q10/3 |
LoseIRWD / S&P -1.84% / 6.17% |
LoseIRWD / S&P -9.37% / -1.06% |
LoseIRWD / S&P IRWD unavailable / 7.39% |
| 2020-Q41/3 |
WinIRWD / S&P 26.70% / 12.15% |
LoseIRWD / S&P -9.08% / -3.72% |
LoseIRWD / S&P IRWD unavailable / -33.42% |
| 2020-Q30/3 |
LoseIRWD / S&P -12.89% / 8.93% |
LoseIRWD / S&P -7.78% / -2.04% |
LoseIRWD / S&P IRWD unavailable / -27.10% |
| 2020-Q21/3 |
LoseIRWD / S&P 2.28% / 20.54% |
WinIRWD / S&P 16.20% / -0.46% |
LoseIRWD / S&P IRWD unavailable / -27.11% |
| 2020-Q11/3 |
LoseIRWD / S&P -24.19% / -19.60% |
WinIRWD / S&P 26.98% / 3.47% |
LoseIRWD / S&P IRWD unavailable / -14.75% |
| 2019-Q42/3 |
WinIRWD / S&P 54.95% / 9.07% |
WinIRWD / S&P 23.59% / 5.36% |
LoseIRWD / S&P IRWD unavailable / 2.99% |
| 2019-Q31/3 |
LoseIRWD / S&P -21.48% / 1.70% |
WinIRWD / S&P 39.54% / 5.02% |
LoseIRWD / S&P IRWD unavailable / 0.21% |
| 2019-Q21/3 |
LoseIRWD / S&P -3.46% / 4.30% |
WinIRWD / S&P 10.88% / 6.64% |
LoseIRWD / S&P IRWD unavailable / 8.65% |
| 2019-Q12/3 |
WinIRWD / S&P 30.60% / 13.65% |
WinIRWD / S&P 9.82% / 8.12% |
LoseIRWD / S&P IRWD unavailable / 14.29% |
| 2018-Q41/3 |
LoseIRWD / S&P -43.88% / -13.52% |
WinIRWD / S&P 16.21% / 9.05% |
LoseIRWD / S&P IRWD unavailable / 18.23% |
| 2018-Q30/3 |
LoseIRWD / S&P -3.45% / 7.71% |
LoseIRWD / S&P 6.39% / 10.21% |
LoseIRWD / S&P IRWD unavailable / 19.06% |
| 2018-Q22/3 |
WinIRWD / S&P 23.91% / 3.43% |
WinIRWD / S&P 22.34% / 9.03% |
LoseIRWD / S&P IRWD unavailable / 14.46% |
| 2018-Q12/3 |
WinIRWD / S&P 2.94% / -0.76% |
WinIRWD / S&P 21.22% / 7.68% |
LoseIRWD / S&P IRWD unavailable / 12.46% |
| 2017-Q41/3 |
LoseIRWD / S&P -4.95% / 6.64% |
WinIRWD / S&P 8.88% / 7.03% |
LoseIRWD / S&P IRWD unavailable / 13.82% |
| 2017-Q31/3 |
LoseIRWD / S&P -16.47% / 4.48% |
WinIRWD / S&P 21.57% / 5.68% |
LoseIRWD / S&P IRWD unavailable / 17.57% |
| 2017-Q22/3 |
WinIRWD / S&P 10.67% / 3.09% |
WinIRWD / S&P 26.98% / 4.83% |
LoseIRWD / S&P IRWD unavailable / 17.74% |
| 2017-Q12/3 |
WinIRWD / S&P 11.58% / 6.07% |
WinIRWD / S&P 39.33% / 3.67% |
LoseIRWD / S&P IRWD unavailable / 13.32% |
| 2016-Q41/3 |
LoseIRWD / S&P -3.72% / 3.82% |
WinIRWD / S&P 83.18% / 2.09% |
LoseIRWD / S&P IRWD unavailable / 7.05% |
| 2016-Q32/3 |
WinIRWD / S&P 21.41% / 3.85% |
WinIRWD / S&P 78.53% / 0.20% |
LoseIRWD / S&P IRWD unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | IRWD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 221.21% | 20.78% |
| Annualized return | 221.21% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | IRWD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -68.05% | 83.14% |
| Annualized return | -20.40% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | IRWD total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -62.08% | 319.30% |
| Annualized return | -9.24% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |